ClinicalTrials.gg
TerminatedNCT04088500Updated Jan 10, 2023Results posted

A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

A Phase 2 interventional study of Nivolumab and Ipilimumab in Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb. Terminated at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Slow accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.

Enrollment
58th of 63
5 · median 54
Started
2020
with 6 others
Phase 2
35 of 63
6 open now
Registered
40th of 63
by date
Lead sponsor
14 of 63
Bristol-Myers Squibb

Among the 63 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 58th largest by enrollment, is one of 7 that started in 2020, is one of 35 in phase 2, and was the 40th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

9 of the 63 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing nivolumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.

03

Conditions studied

  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Participants and Target Disease Characteristics- -

  • Confirmed disease progression by 1.1 criteria on nivolumab maintenance after induction with ipilimumab and nivolumab
  • Progress of maintenance treatment of nivolumab by RECIST. Pathology report must be submitted for embedded tissue block or tumor tissue.

Age and Reproduction Sexually active males with must agree to instructions for and fetal protection.

WOCBP need to use contraception throughout the study and for 5 months post treatment.

Exclusion criteria

Exclusion Criteria disease statement

  • Active central nervous system
  • Participants with an active autoimmune disease, diabetes mellitus, skin disorders, hyperthyroidism requiring hormone treatments are permitted to enroll.
  • Any major surgery 28 days before 1st treatment Concomitant Therapy
  • participants that have received a within 30 days of treatment.
  • use of agent or device with in 28 days before first dosage study treatment.

Physical and Laboratory Test Findings Allergies and Adverse Drug Reaction Age and Reproduction

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Nivolumab + Ipilimumab (combination)

    Nivolumab + Ipilimumab (combination) Q3W for 4 doses

    Biological: Nivolumab · Biological: Ipilimumab

Interventions

  • BiologicalNivolumab

    Specific dose on specific days

    Also known as: Opdivo

  • BiologicalIpilimumab

    Specific dose on specific days

06

What researchers measure

Primary outcomes

  1. Disease Control Rate (DCR)

    Disease Control Rate (DCR) is defined as the percentage of participants who achieve a confirmed best response of complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months after first treatment dose per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

    Time frame: From first dose up to approximately 14 months

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from first dose to the date of death from any cause. For participants that are alive, their survival time will be censored at the date of last contact ("last known alive date"). OS will be censored for participants at the date of first dose if they were treated but had no follow-up.

    Time frame: From first dose to the date of death from any cause (up to approximately 14 months)

  2. Overall Response Rate (ORR)

    Overall Response Rate (ORR) is defined as the percentage of participants who achieve a best response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose and the date of objectively documented progression criteria or the date of subsequent therapy, whichever occurs first (up to approximately 14 months)

  3. Duration of Response (DOR)

    Duration of Response (DOR) is defined as the time between the date of first documented response (complete response (CR) or partial response (PR)) to the date of the first documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of the first documented progression or death due to any cause, whichever occurs first (up to approximately 14 months)

  4. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as the time between the date of first dose and the first date of documented progression, as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or death due to any cause, whichever occurs first. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: From first dose to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 14 months)

  5. Time to Objective Response (TTR)

    Time to Objective Response (TTR) is defined as the time between the date of the first dose and the first confirmed documented response (complete response (CR) or partial response (PR)) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the first confirmed documented response (up to approximately 14 months)

  6. The Number of Participants Experiencing Adverse Events (AEs)

    The number of participants with any grade adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose and 100 days after lost dose (up to approximately 14 months)

07

Results

Posted Jan 10, 2023
Limitations and caveats
The study was terminated early, leading to small numbers of participants analyzed.

Participant flow

Participant flow — Overall Study
MilestoneNIVO 3 + IPI 1
Started5
Completed0
Not completed5
Withdrew: Reason unknown1
Withdrew: Participant withdrew consent1
Withdrew: Disease progression3

Outcome measures

PrimaryDisease Control Rate (DCR)

Disease Control Rate (DCR) is defined as the percentage of participants who achieve a confirmed best response of complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months after first treatment dose per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

Time frame:
From first dose up to approximately 14 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsNIVO 3 + IPI 1
Disease Control Rate (DCR)60.0 (14.7 to 94.7)
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time from first dose to the date of death from any cause. For participants that are alive, their survival time will be censored at the date of last contact ("last known alive date"). OS will be censored for participants at the date of first dose if they were treated but had no follow-up.

Time frame:
From first dose to the date of death from any cause (up to approximately 14 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsNIVO 3 + IPI 1
Overall Survival (OS)NA (11.01 to NA)
SecondaryOverall Response Rate (ORR)

Overall Response Rate (ORR) is defined as the percentage of participants who achieve a best response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose and the date of objectively documented progression criteria or the date of subsequent therapy, whichever occurs first (up to approximately 14 months)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsNIVO 3 + IPI 1
Overall Response Rate (ORR)0.0 (0.0 to 52.2)
SecondaryDuration of Response (DOR)

Duration of Response (DOR) is defined as the time between the date of first documented response (complete response (CR) or partial response (PR)) to the date of the first documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of the first documented progression or death due to any cause, whichever occurs first (up to approximately 14 months)

No measurements were reported for this outcome.

SecondaryProgression Free Survival (PFS)

Progression Free Survival (PFS) is defined as the time between the date of first dose and the first date of documented progression, as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or death due to any cause, whichever occurs first. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
From first dose to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 14 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsNIVO 3 + IPI 1
Progression Free Survival (PFS)NA (4.60 to NA)
SecondaryTime to Objective Response (TTR)

Time to Objective Response (TTR) is defined as the time between the date of the first dose and the first confirmed documented response (complete response (CR) or partial response (PR)) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the first confirmed documented response (up to approximately 14 months)

No measurements were reported for this outcome.

SecondaryThe Number of Participants Experiencing Adverse Events (AEs)

The number of participants with any grade adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose and 100 days after lost dose (up to approximately 14 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs)
ParticipantsNIVO 3 + IPI 1
The Number of Participants Experiencing Adverse Events (AEs)5

Adverse events

Collected over All-cause mortality was assessed from first dose to study completion (up to approximately 14 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 14 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NIVO 3 + IPI 11/5 (20%)2/5 (40%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventNIVO 3 + IPI 1
HYPOVOLAEMIAMetabolism and nutrition disorders1/5
HAEMATURIARenal and urinary disorders1/5
Most frequent other events
Showing 10 of 28
Most frequent other events
EventNIVO 3 + IPI 1
FATIGUEGeneral disorders2/5
DECREASED APPETITEMetabolism and nutrition disorders2/5
DYSPNOEA EXERTIONALRespiratory, thoracic and mediastinal disorders2/5
PRURITUSSkin and subcutaneous tissue disorders2/5
RASHSkin and subcutaneous tissue disorders2/5
ANAEMIABlood and lymphatic system disorders1/5
VERTIGOEar and labyrinth disorders1/5
ABDOMINAL PAINGastrointestinal disorders1/5
ABDOMINAL PAIN LOWERGastrointestinal disorders1/5
ABDOMINAL PAIN UPPERGastrointestinal disorders1/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NIVO 3 + IPI 1
Mean62.2 ± 11.0
Age, Customized
Age, Customized(Participants)NIVO 3 + IPI 1
< 65 years2
>= 65 AND < 75 years3
Sex: Female, Male
Sex: Female, Male(Participants)NIVO 3 + IPI 1
Female0
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NIVO 3 + IPI 1
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NIVO 3 + IPI 1
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White4
More than one race0
Unknown or Not Reported0
08

Study locations

12 sites
  • Washington University School of Medicine in St. Louis WUSTL
    Saint Louis, Missouri 63108, United States
  • Local Institution
    Calgary, Alberta T3B 3L1, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • BC Cancer Agency - Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Atlantic Clinical Cancer Research Unit
    Halifax, Nova Scotia B3H 1V7, Canada
  • Hamilton Health Sciences (HHS) - Juravinski Cancer Centre (JCC)
    Hamilton, Ontario L8V 5C2, Canada
  • Toronto Sunnybrook Regional Cancer Ctr
    Toronto, Ontario M4N 3M5, Canada
  • Local Institution
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution
    Montreal, Quebec H2X 3E4, Canada
  • Local Institution - 0005
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution
    Quebec City, Quebec G2L 2Z3, Canada
  • Local Institution - 0006
    Sherbrooke, Quebec J1H 5N4, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2021, 14 months.

Results were first posted in Jan 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2019
First posted
Sep 12, 2019
StartActual
Sep 3, 2020
Primary completionActual
Nov 15, 2021
CompletionActual
Nov 15, 2021
Results first posted
Jan 10, 2023
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04088500
Responsible party
Sponsor
First posted
Sep 12, 2019
Start date
Sep 3, 2020
Primary completion
Nov 15, 2021
Completion
Nov 15, 2021
Results posted
Jan 10, 2023
Last update
Jan 10, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion